WallStSmart

Boston Scientific Corp (BSX)vsTrinity Biotech plc (TRIB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 32511% more annual revenue ($20.07B vs $61.55M). BSX leads profitability with a 14.4% profit margin vs -51.6%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

TRIB

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for TRIB.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

TRIB1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
18.1%8/10

18.1% revenue growth

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

TRIB4 concerns · Avg: 2.3/10
Market CapQuality
$15.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-19.1%2/10

ROE of -19.1% — below average capital efficiency

EPS GrowthGrowth
-77.3%2/10

Earnings declined 77.3%

Free Cash FlowQuality
$-77,1092/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : TRIB

The strongest argument for TRIB centers on Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : TRIB

The primary concerns for TRIB are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BSX carries more volatility with a beta of 0.70 — expect wider price swings.

TRIB is growing revenue faster at 18.1% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 37/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Trinity Biotech plc

HEALTHCARE · MEDICAL DEVICES · USA

Trinity Biotech plc acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point of care (POC) segments of the diagnostic market in the United States, Africa, Asia and Europe. The company is headquartered in Bray, Ireland.

Want to dig deeper into these stocks?